BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35692766)

  • 1. Efficacy and Safety of Placebo During the Maintenance Therapy of Ovarian Cancer in Randomized Controlled Trials: A Systematic Review and Meta-analysis.
    Wang JF; Zhao LB; Bin YD; Zhang KL; Sun C; Wang YR; Feng X; Ji J; He LS; Chen FY; Li QL
    Front Oncol; 2022; 12():796983. PubMed ID: 35692766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
    Wei Y; He L; Liu T; Guo T; Xie C; Jia J; Lin Y; Liu J; Fan J
    Front Pharmacol; 2024; 15():1372077. PubMed ID: 38584601
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials.
    Xie Y; Zhou F
    Front Pharmacol; 2024; 15():1423891. PubMed ID: 38860165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
    Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
    Hao J; Liu Y; Zhang T; He J; Zhao H; An R; Xue Y
    Crit Rev Oncol Hematol; 2021 Jan; 157():103145. PubMed ID: 33254040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis.
    Qian X; Qin J; Pan S; Li X; Pan Y; Ma S
    PLoS One; 2015; 10(9):e0139026. PubMed ID: 26402447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with
    Ma J; Deng H; Li J; Hu S; Yang Y; Liu S; Han X
    Cancer Manag Res; 2019; 11():3061-3078. PubMed ID: 31114351
    [No Abstract]   [Full Text] [Related]  

  • 8. The role systematic lymphadenectomy plays in determining the survival outcome for advanced ovarian cancer patients: a meta-analysis.
    Xu D; Xue J; Rozan R; Li L
    Ann Palliat Med; 2020 May; 9(3):912-920. PubMed ID: 32389005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
    Guo C; Yan C; Qu L; Du R; Lin J
    Arch Gynecol Obstet; 2021 Feb; 303(2):285-311. PubMed ID: 33222040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance treatment with different strategies in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Cai H; Lin Y; Li W; Li X
    Clin Lung Cancer; 2013 Jul; 14(4):333-41. PubMed ID: 23276822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.
    Blank O; von Tresckow B; Monsef I; Specht L; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007110. PubMed ID: 28447341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral versus intravenous fluoropyrimidines for colorectal cancer.
    Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
    Li X; Xu S; Tan Y; Chen J
    Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and toxicities of combination maintenance therapy in the treatment of advanced colorectal cancer: a meta-analysis of randomized controlled trials.
    Lin F; Li H; Wang J; Wang F
    Biosci Rep; 2018 Oct; ():. PubMed ID: 30355651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Wu YS; Shui L; Shen D; Chen X
    Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Novel Hormonal Therapies for Non-Metastatic Castration-Resistant Prostate Cancer: An Update From Mature Overall Survival Data.
    Maggi M; Salciccia S; Del Giudice F; Busetto GM; Falagario UG; Carrieri G; Ferro M; Porreca A; Di Pierro GB; Fasulo V; Frantellizzi V; De Vincentis G; De Berardinis E; Sciarra A
    Front Oncol; 2021; 11():700258. PubMed ID: 34169003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis.
    Zhou M; Yu P; Qu X; Liu Y; Zhang J
    PLoS One; 2013; 8(12):e81858. PubMed ID: 24324725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
    Gordon M; Naidoo K; Akobeng AK; Thomas AG
    Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.